The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

Shares MSCI Denmark ETF (EDEN) is currently trading at an attractive earnings multiple relative to history. See why the ...

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Lotte Bjerre Knudsen lives comfortably in this pleasant, but not showy, £900,000 apartment in central Copenhagen with her ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Similarly, SKF, a Swedish multinational known for industrial and automotive solutions, operates its Global Technical Centre ...